Plain-English translation of NCT07221851 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new form of growth hormone called lonapegsomatropin that is given once per week, compared to the standard daily growth hormone injection (somatropin). The goal is to see if the weekly injection works just as well to help children and adolescents grow taller, while being more convenient because it requires fewer injections.
Children with certain genetic or developmental conditions don't grow at a normal rate, even though their bodies produce enough natural growth hormone. Currently, the only treatment is daily injections, which can be burdensome for families. This medication is designed to work longer in the body so children only need one injection per week instead of seven, making treatment easier to manage.
You likely qualify if…
You likely don't qualify if…
You will visit study clinics multiple times over 2 years for check-ups, blood tests, and bone age X-rays to measure how well the treatment is working. Half of participants will receive the new weekly injection for the full 2 years, while the other half will receive daily injections for 1 year and then switch to weekly injections for the second year. All injections are given under the skin (like an insulin shot) and can be done at home.
AI-generated summary from trial data · Oct 4, 2026 · Not medical advice
United States